RxSight downgraded to Equal Weight from Overweight at Morgan Stanley

Morgan Stanley downgraded RxSight (RXST) to Equal Weight from Overweight with a price target of $9, down from $20. Morgan Stanley says it doesn’t have visibility on RxSight’s near-term growth to remain Overweight following the significant slowdown in LDD placements in Q2 as well as a tougher competitive environment, the analyst tells investors in a research note.